IL252324B - A solid dispersion comprising arn-509 and a poly(meth)acrylate copolymer, particles and pharmaceutical formulation comprising the same, methods of their preparation and uses thereof - Google Patents

A solid dispersion comprising arn-509 and a poly(meth)acrylate copolymer, particles and pharmaceutical formulation comprising the same, methods of their preparation and uses thereof

Info

Publication number
IL252324B
IL252324B IL252324A IL25232417A IL252324B IL 252324 B IL252324 B IL 252324B IL 252324 A IL252324 A IL 252324A IL 25232417 A IL25232417 A IL 25232417A IL 252324 B IL252324 B IL 252324B
Authority
IL
Israel
Prior art keywords
preparation
meth
poly
particles
methods
Prior art date
Application number
IL252324A
Other languages
English (en)
Hebrew (he)
Other versions
IL252324A0 (en
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL252324(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of IL252324A0 publication Critical patent/IL252324A0/en
Publication of IL252324B publication Critical patent/IL252324B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL252324A 2014-12-05 2017-05-16 A solid dispersion comprising arn-509 and a poly(meth)acrylate copolymer, particles and pharmaceutical formulation comprising the same, methods of their preparation and uses thereof IL252324B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14196591 2014-12-05
PCT/US2015/063667 WO2016090101A1 (en) 2014-12-05 2015-12-03 Anticancer compositions

Publications (2)

Publication Number Publication Date
IL252324A0 IL252324A0 (en) 2017-07-31
IL252324B true IL252324B (en) 2021-10-31

Family

ID=52006905

Family Applications (1)

Application Number Title Priority Date Filing Date
IL252324A IL252324B (en) 2014-12-05 2017-05-16 A solid dispersion comprising arn-509 and a poly(meth)acrylate copolymer, particles and pharmaceutical formulation comprising the same, methods of their preparation and uses thereof

Country Status (31)

Country Link
US (3) US20170360707A1 (OSRAM)
EP (2) EP3842034B1 (OSRAM)
JP (1) JP6767368B2 (OSRAM)
KR (1) KR102348325B1 (OSRAM)
CN (2) CN115837010B (OSRAM)
AR (1) AR102924A1 (OSRAM)
AU (1) AU2015358493B2 (OSRAM)
CA (1) CA2969661C (OSRAM)
CL (1) CL2017001372A1 (OSRAM)
CO (1) CO2017005573A2 (OSRAM)
CR (1) CR20170217A (OSRAM)
CY (1) CY1123856T1 (OSRAM)
DK (1) DK3226842T3 (OSRAM)
EA (1) EA035988B1 (OSRAM)
ES (2) ES3021508T3 (OSRAM)
HR (1) HRP20201902T1 (OSRAM)
HU (1) HUE051888T2 (OSRAM)
IL (1) IL252324B (OSRAM)
LT (1) LT3226842T (OSRAM)
MA (2) MA41108B1 (OSRAM)
MD (1) MD3226842T2 (OSRAM)
MX (1) MX384382B (OSRAM)
NI (1) NI201700069A (OSRAM)
PL (1) PL3226842T3 (OSRAM)
PT (1) PT3226842T (OSRAM)
RS (1) RS61466B1 (OSRAM)
SG (1) SG11201704264UA (OSRAM)
SI (1) SI3226842T1 (OSRAM)
TW (1) TWI683662B (OSRAM)
UA (1) UA121123C2 (OSRAM)
WO (1) WO2016090101A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
PT3226843T (pt) 2014-12-05 2021-07-07 Aragon Pharmaceuticals Inc Composições anticancro
KR20200141533A (ko) 2014-12-05 2020-12-18 아라곤 파마슈티컬스, 인코포레이티드 항암 조성물
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
US11708463B2 (en) * 2018-04-06 2023-07-25 Capsugel Belgium Nv Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
WO2020144646A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Apalutamide dispersed in applesauce for treating prostate cancer
JP2022524289A (ja) 2019-01-30 2022-05-02 ヤンセン ファーマシューティカ エヌ．ベー． 分子サブタイプに基づいて前立腺癌を治療する方法
EP3917519A1 (en) 2019-01-30 2021-12-08 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US11723898B2 (en) 2019-11-04 2023-08-15 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
WO2022049523A1 (en) 2020-09-04 2022-03-10 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
TW202444354A (zh) 2023-03-16 2024-11-16 瑞士商拜耳保健消費品股份有限公司 用於治療荷爾蒙敏感性前列腺癌生化復發患者之雄激素受體拮抗劑

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140100256A1 (en) * 2012-09-11 2014-04-10 Bend Research Formulations of enzalutamide

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12032003A3 (sk) 2001-04-02 2004-03-02 Astrazeneca Ab Farmaceutická formulácia obsahujúca 4'-kyano-alfa', alfa', alfa'-trifluór-3-(4-fluórfenylsulfonyl)-2-hydroxy-2- metylpropiono-m-toluidín a PVP
JPWO2003077827A1 (ja) * 2002-03-19 2005-07-14 日本新薬株式会社 医薬固体分散体の製造方法
JP2007518670A (ja) * 2003-12-15 2007-07-12 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 苦味のある薬物、及びｐＨ感受性ポリマーを含む風味マスクされた医薬組成物
LT2656842T (lt) * 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
KR101819199B1 (ko) * 2010-02-16 2018-01-16 아라곤 파마슈티컬스, 인코포레이티드 안드로겐 수용체 조절제 및 이의 용도
EP2721003B1 (en) * 2011-06-15 2018-01-03 The United States of America, as Represented by The Secretary, Department of Health and Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
CA3008345C (en) 2012-06-07 2019-10-22 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
EA030128B1 (ru) * 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
PE20151335A1 (es) * 2013-01-22 2015-09-18 Hoffmann La Roche Composicion farmaceutica con biodisponibilidad mejorada
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
CA2920317A1 (en) * 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015118015A1 (en) * 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140100256A1 (en) * 2012-09-11 2014-04-10 Bend Research Formulations of enzalutamide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EVONIK, " EUDRAGIT BROCHURE", 15 December 2012 (2012-12-15) *
NICOLA J. CLEGG ET.AL, " ARN-509: A NOVEL ANTI-ANDROGEN FOR PROSTATE CANCER TREATMENT", 15 March 2012 (2012-03-15) *

Also Published As

Publication number Publication date
CA2969661A1 (en) 2016-06-09
CL2017001372A1 (es) 2018-01-05
EP3226842B1 (en) 2020-11-25
SI3226842T1 (sl) 2021-04-30
NI201700069A (es) 2017-10-31
HUE051888T2 (hu) 2021-03-29
TWI683662B (zh) 2020-02-01
KR20170086657A (ko) 2017-07-26
EP3842034B1 (en) 2025-02-12
CN115837010A (zh) 2023-03-24
DK3226842T3 (da) 2021-01-25
UA121123C2 (uk) 2020-04-10
KR102348325B1 (ko) 2022-01-06
MX384382B (es) 2025-03-14
PL3226842T3 (pl) 2021-07-12
MA55404A (fr) 2022-02-02
IL252324A0 (en) 2017-07-31
SG11201704264UA (en) 2017-06-29
JP6767368B2 (ja) 2020-10-14
WO2016090101A1 (en) 2016-06-09
EA201791252A1 (ru) 2017-10-31
PT3226842T (pt) 2020-12-23
EA035988B1 (ru) 2020-09-09
ES3021508T3 (en) 2025-05-27
JP2017536401A (ja) 2017-12-07
LT3226842T (lt) 2021-03-25
CY1123856T1 (el) 2022-05-27
TW201632187A (zh) 2016-09-16
CN106999430A (zh) 2017-08-01
AU2015358493A1 (en) 2017-06-08
CA2969661C (en) 2023-04-25
US20170360707A1 (en) 2017-12-21
AR102924A1 (es) 2017-04-05
US20240293321A1 (en) 2024-09-05
HRP20201902T1 (hr) 2021-07-23
CN115837010B (zh) 2025-03-14
EP3842034A1 (en) 2021-06-30
EP3226842A1 (en) 2017-10-11
MA41108A (fr) 2016-06-09
BR112017011787A2 (pt) 2017-12-26
MA41108B1 (fr) 2021-03-31
RS61466B1 (sr) 2021-03-31
MX2017007201A (es) 2018-01-30
CR20170217A (es) 2017-08-30
ES2839128T3 (es) 2021-07-05
AU2015358493B2 (en) 2021-05-06
CO2017005573A2 (es) 2017-09-29
US20220151931A1 (en) 2022-05-19
MD3226842T2 (ro) 2021-03-31

Similar Documents

Publication Publication Date Title
IL252324B (en) A solid dispersion comprising arn-509 and a poly(meth)acrylate copolymer, particles and pharmaceutical formulation comprising the same, methods of their preparation and uses thereof
EP3191546A4 (en) Emulsion polymers including one or more 1,1-disubstituted alkene compounds, emulsion methods, and polymer compositions
EP3188763A4 (en) Methods and compositions for rna-directed target dna modification
EP3270932A4 (en) Cross-linked polymer modified nanoparticles
EP3260485A4 (en) Superabsorbent polymer
ZA201805104B (en) Preparation method for polymer and applications thereof
EP3285906A4 (en) Porous article having polymer binder sub-micron particle
EP3129048A4 (en) Antibodies, pharmaceutical compositions and uses thereof
EP3296326A4 (en) Flat elliptical polymer particles, and use thereof
EP3190100A4 (en) Polymerizable compound, polymer, polymerizable composition, and film
EP3218435A4 (en) Composition comprising polymer particles, a hydrocarbon-based oil and a hydrocarbon-based block copolymer, and process using the same
EP3246351A4 (en) Triazine-ring-containing polymer and composition containing same
EP3357934B8 (en) Polymer particles and use thereof
EP3119819A4 (en) Tri-substituted aromatic-containing monomers, copolymers and methods for use
EP3321308A4 (en) Superabsorbent polymer preparation method, and superabsorbent polymer
WO2016096085A8 (en) Particles for electrophoretic displays
GB201616843D0 (en) Polymerizable composition comprising compound having mesogenic group, and polymer thereof
EP3521323A4 (en) FLUORESCENT RESIN PARTICLES AND APPLICATION THEREOF
EP3102613A4 (en) Polymer particles and uses thereof
PL3478663T3 (pl) Polimer funkcjonalizowany laktamem, jego kompozycje i zastosowanie
EP3146962A4 (en) Allisartan isoproxil solid dispersion and pharmaceutical composition thereof
EP3162835A4 (en) Monomer composition, and curable composition including same
EP3268412A4 (en) Functionalized f-poss monomer compositions and uses thereof
ZA201801436B (en) Penflufen polymer particles
EP3165219A4 (en) Allisartan isoproxil solid dispersion and pharmaceutical composition comprising same